Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Regulator of G protein signalling 9-2 (Rgs9-2) is crucial for G protein-coupled receptor (GPCR) signaling in the striatum.
• Rgs9-2 interacts with Gα subunits, Gβ5, and R7BP, influencing CNS drug actions.
• Previous studies linked Rgs9-2 to mu opioid receptor (MOR) agonist effects.

Purpose of the Study:

• To investigate the role of Rgs9-2 in modulating opiate addiction and analgesia using novel genetic tools.
• To elucidate the specific mechanisms by which Rgs9-2 influences morphine's effects in the brain.

Main Methods:

• Utilized adeno-associated viruses (AAVs) for targeted Rgs9-2 expression in the dorsal and ventral striatum (nucleus accumbens, NAc) of adult mice.
• Employed optogenetics to activate specific neuronal populations, including Rgs9-2-expressing neurons and those enriched in D1 or D2 dopamine receptors.
• Assessed behavioral responses to morphine, focusing on reward, dependence, analgesia, and tolerance development.

Main Results:

• Rgs9-2 activity in the NAc was confirmed to modulate morphine reward and dependence, consistent with prior knockout studies.
• Rgs9-2 in the NAc significantly impacts morphine's analgesic effects and the development of analgesic tolerance.
• Optogenetic activation of Rgs9-2-expressing or D1 dopamine receptor neurons accelerated morphine tolerance, while D2 receptor neuron activation did not.

Conclusions:

• Rgs9-2 in the nucleus accumbens plays a critical role in regulating the rewarding, dependence-inducing, and analgesic properties of opioids.
• Specific neuronal pathways involving Rgs9-2 and dopamine receptors in the NAc are implicated in the development of opioid tolerance.
• These findings offer new insights into the signal transduction mechanisms underlying opiate actions in the striatum.